Adam Feuerstein on Muck Rack

Adam Feuerstein

As seen in: The Street, STAT

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs into New Clinical Trials — Vertex Pharmaceuticals ( VRTX) confirmed Tuesday that the next generation of cystic fibrosis drugs from its research labs will begin mid-stage clinical trials by the end of the year. Vertex is developing these drugs, VX-440 and VX-152, to become components of new combination regimens to treat the underlying cause of cystic fibrosis.

Bear Thesis on Corbus Pharma Could Cause a Crash Landing for High-Flying Biotech Stock — Corbus Pharmaceuticals ( CRBP) is the top-performing biotech stock of the year but it's headed for a big fall. Says who? My most reliable and skeptical healthcare investor source says so. I can't share this fund manager's identity with you, but you've read his accurate biotech bear calls before in my columns.

Global Blood, FDA Reach Agreement on Pivotal Trial Design for Sickle Cell Disease Drug — Global Blood Therapeutics ( GBT) unveiled Monday the design of a pivotal, phase III clinical trial for its experimental drug GBT440 in sickle cell disease. Most important, the study's primary efficacy endpoint will measure the ability of GBT440 to increase levels of oxygen-carrying hemoglobin in sickle cell patients compared to a placebo, Global Blood said.

Alkermes depression drug finds success on third study attempt $ALKS — A third late-stage clinical trial of Alkermes' ( ALKS) experimental antidepressant ALKS 5461 delivered positive results Thursday, breathing new life into the drug following two negative clinical trials announced in January. Alkermes plans to meet with the U.S.

Why Ariad Pharmaceuticals (ARIA) Stock Is Sliding Today — NEW YORK ( TheStreet) -- Shares of Ariad Pharmaceuticals ( ARIA) were falling on heavy trading volume mid-Thursday afternoon after Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD) sent a letter to the company asking for more information on the pricing of its Iclusig leukemia drug.

Gilead Sciences Advances Fatty Liver Drug for Reasons Causing Some Head Scratching — An experimental drug known as GS-4997 from Gilead Sciences ( GILD) reduced the buildup of scar tissue in the livers of patients with nonalcoholic steatohepatitis (NASH), better known as fatty liver disease, according to results from a phase II study announced Thursday.

Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble — The bankers at Citigroup and J.P. Morgan must have been advising Puma Biotechnology ( PBYI) and its CEO Alan Auerbach to pull the proposed stock offering. Investor demand was simply not there to close the $150 million deal at a reasonable price. On Wednesday afternoon, as Citi and J.P.

Celgene skips the placebo, fails drug development 101 $CELG — Celgene ( CELG) wasted everyone's time by running a Crohn's disease study of GED-0301 without including a placebo arm. Absent a placebo arm for comparison, the GED-0301 Crohn's data presented Tuesday (announced via press release on Monday) are largely uninterpretable.

Pardon me, but I have a few things to say... Trump, Bernie, Radius, Ariad $RDUS $ARIA $IBB — Pardon me, but I have a few things to say about... 1. Add Donald Trump to the list of politicians driving down biotech stock prices. Trump's self-immolating campaign for the presidency and the turmoil it's creating within the Republican party has healthcare investors more concerned than ever about Democrats winning the White House and Congress.

PTC Therapeutics Getting Cold Shoulder from Regulators on Duchenne Drug Appeal — PTC Therapeutics ( PTCT) is having a tough time convincing regulators on both sides of the Atlantic Ocean to reconsider the marketing application for its Duchenne muscular dystrophy drug Translarna. On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
More Articles →
Oct 25, 2016

@abbynach The $CRBP bear thesis hinges on failure of the resunab study. Results later this quarter.

Oct 25, 2016

$VRTX announced planned start of ph2 studies of next gen CF drugs VX-440 and VX-152. Finally!

Oct 25, 2016

@bradloncar I hope $VRTX provides a meaningful update on status of triple combo CF studies. Lack of transparency getting annoying.

Oct 25, 2016

@rymankoly I explained the bear thesis for a biotech stock. Why is that unethical?

Oct 25, 2016

@djr709 Why? You should focus on the bear thesis. You’ll learn.

Oct 25, 2016

$BIIB Q3 earnings tomorrow morning. Tecfidera consensus sales $1 billion, per Factset.

Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio